Radiotherapy of salivary gland tumours

Area of Science:

• Oncology
• Radiotherapy
• Head and Neck Surgery

Background:

• Salivary gland tumors constitute 5-10% of head and neck malignancies.
• Surgery is the primary treatment, with radiotherapy indicated for advanced or high-risk malignant tumors.
• Diagnosis involves imaging (MRI, ultrasound) and fine-needle aspiration.

Purpose of the Study:

• To update indications and recommendations for radiotherapy in salivary gland tumors.
• To provide guidance on techniques, doses, target volumes, and organ-at-risk constraints.
• To emphasize personalized radiotherapy based on tumor characteristics and multidisciplinary discussion.

Main Methods:

• Review of French Society for Radiotherapy and Oncology (SFRO) guidelines.
• Analysis of factors influencing radiotherapy decisions (stage, histology, margins, invasion).
• Consideration of multidisciplinary network (Refcor) recommendations for rare cancers.

Main Results:

• Radiotherapy is crucial for malignant salivary gland tumors with specific adverse features (e.g., advanced stage, positive margins, high grade).
• Personalized treatment planning is essential, considering tumor extent, histology, and patient factors.
• Recurrent pleomorphic adenomas may also warrant radiotherapy upon multidisciplinary review.

Conclusions:

• Updated SFRO recommendations provide a framework for optimal radiotherapy in salivary gland tumors.
• Personalized radiotherapy, informed by multidisciplinary expertise, is key to effective management.
• These guidelines aim to standardize and improve treatment outcomes for these rare malignancies.